Progenity, Inc.

40 articles about Progenity, Inc.

• Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results

  11/10/2021

  Progenity, Inc., an innovative biotechnology company, provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

• Progenity Appoints Adi Mohanty as Chief Executive Officer

  11/9/2021

  Progenity, Inc., an innovative biotechnology company, announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021.

• Progenity Announces Appointment of Jill Howe to its Board of Directors

  11/4/2021

  Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Jill Howe to its board of directors effective November 3, 2021.

• Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update

  11/3/2021

  Progenity, Inc. today announced that it will report third quarter 2021 financial results on Wednesday, November 10, 2021 after the close of financial markets.

• Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock

  10/26/2021

  Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock

• Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference

  10/19/2021

  Progenity, Inc. announced today that the company will participate in the fourth annual IBD Innovate Product Development for Crohn’s & Colitis virtual conference, hosted by the Crohn’s & Colitis Foundation, November 18-19, 2021.

• Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies

  10/13/2021

  Progenity, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued four patents related to its ingestible technologies for delivery of therapeutics via the gastrointestinal (GI) tract.

• Progenity Announces Closing of $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules

  10/6/2021

  Progenity, Inc., an innovative biotechnology company, announced the closing of its previously announced registered direct offering of 13,333,334 shares of the Company's common stock, at a purchase price of $1.50 per share, priced at a premium to market under Nasdaq rules for gross proceeds of approximately $20 million, before deducting the placement agent's fees and other offering expenses.

• Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules

  10/4/2021

  Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 13,333,334 shares of the Company's common stock, at a purchase price of $1.50 per share

• Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference

  9/21/2021

  Progenity, Inc. announced today that the company will participate in the 11th  annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 28-29, 2021 in Boston.

• Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices

  7/23/2020

  Progenity, Inc. announced that it has entered into agreements with the Department of Justice and the Department of Health and Human Services that resolve civil and criminal investigations by such agencies related to certain past business, promotional, and billing practices.

• 

  BioSpace Movers & Shakers, May 29

  5/29/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Movers & Shakers, May 1

  5/1/2020

  Life sciences and pharma companies strengthen their leadership teams and board with this week's Movers & Shakers.
• 

  BioSpace Movers & Shakers, Oct. 25

  10/25/2019

  Pharma and life sciences companies strengthen their executive and leadership teams with this week's appointments.
• 

  BioSpace Movers and Shakers, Aug. 9

  8/9/2019

  Biopharma companies strengthen their senior leadership teams and boards of directors.
• 

  BioSpace Movers and Shakers, June 7

  6/7/2019

  Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
• 

  BioSpace Movers and Shakers: March 1

  3/1/2019

  Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.

• Progenity to Present at Three Key Investor Conferences

  2/25/2019

  Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, announced that Harry Stylli, Ph.D., CEO, will be participating in several upcoming investor conferences.

• Progenity Announces Expansion of Board of Directors

  2/21/2019

  Company Focused on Diagnostic and Therapeutic Precision Medicine Solutions in Prenatal and Perinatal Healthcare, Oncology, and Gastroenterology

• 

  San Diego Biotech Progenity Banks $125M for Precision Medicine R&D

  11/7/2017

  Progenity snagged $125M in funding that will allow the company to accelerate development of its gastrointestinal platform.